- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05182242
Comparison of the Non-invasive Approach and Fetal Exome Sequencing in Prenatal Diagnosis When Fetal Ultrasound Signs Are Discovered (DPNI-Exome)
The discovery of congenital malformations and/or non-specific signs by ultrasound (5% of pregnancies) represents a real medical challenge. Their prognosis is variable depending on the underlying etiology, ranging from acquired fetopathies to rare genetic diseases. In France, the diagnostic approach is currently based on imaging examinations (ultrasound, brain MRI, 3D bone scans, etc.) and/or biological examinations, generally on invasive sampling (trophoblast biopsy, amniocentesis or fetal blood puncture) with infectious (CMV, toxoplasmosis, parvovirus B19, etc.), metabolic (enzymes in the bloodstream, etc.), and genetic (standard karyotype, FISH, array CGH and targeted gene sequencing) investigations. The yield of this strategy is about 30%, leaving 70% of couples without a possible prognosis.
Over the last decade, medical genetics has undergone a technological revolution with the development of high-throughput DNA sequencing (HTS) allowing the analysis of targeted genes (panel) or the exome (ES). International studies published on the use of ES in prenatal diagnosis (PND) have become more common, with variable inclusion criteria, resulting in diagnostic rates between 15 and 36%, higher than those of array CGH (8-15%). In France, FHU TRANSLAD coordinates the national pilot study AnDDI-PRENATOME, which has made it possible to remove the technological barriers for PND ES and to obtain a diagnostic yield of 39% in 33 days on average.
In parallel, the recent development of NIPD (Non-invasive prenatal screening) on free fetal DNA circulating in maternal blood has made it possible to propose a non-invasive strategy. However, this technique is currently used in prenatal care only in a few indications: determination of the fetal sex, search for aneuploidies, analysis of the fetal rhesus status or, more rarely, the targeted diagnosis of monogenic diseases. The team in Strasbourg has recently conducted a pilot study using an NIPD-panel in couples with a history of neomutation in a gene responsible for intellectual disability, which has demonstrated the feasibility of capturing and then sequencing a panel of 500 genes on free fetal DNA circulating in maternal blood.
As high-depth exome sequencing from small amounts of DNA is now affordable and feasible, the investigators wish to compare invasive and non-invasive approaches for the discovery of fetal malformations on ultrasound: a trio exome analysis will be performed in parallel to circulating fetal DNA and fetal DNA extracted after an invasive puncture in order to compare the diagnostic performance of these two approaches.
The investigators propose a pilot study in order to prepare an organizational evaluation including an evaluation of the stakes for coordination and interactions between professionals, the relevance of the system (acceptability, expectations, satisfaction of couples and professionals...), its effectiveness and efficiency. The aim of this pilot project will be to observe the organizational impact on the Plurldisciplinary Centers for Prenatal Disagnostics and the genetic laboratories, and to refine the indicators necessary for monitoring the system; it will also involve conducting exploratory interviews with professionals and couples in order to prepare the qualitative study that will subsequently make it possible to evaluate the relevance of the organization.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sophie NAMBOT
- Phone Number: 03 80 29 53 13
- Email: sophie.nambot@chu-dijon.fr
Study Locations
-
-
-
Dijon, France
- Recruiting
- CHU Dijon Bourgogne
-
Contact:
- Sophie NAMBOT
- Phone Number: 03 80 29 53 13
- Email: sophie.nambot@chu-dijon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant women with prenatal discovery of fetal malformations on ultrasound that may justify the performance of a fetal exome sequencing (e.g., multiple malformations and/or severe brain malformation, microphthalmia, bone damage, severe cardiac damage, etc.) who will have or are having an invasive prenatal sample for array CGA diagnosis and for which the results of the ES could change the outcome of the pregnancy
- Sufficient quantity of fetal sample (amniotic fluid or fetal blood or fetal DNA) for the collection of an additional sample for the ES
- Ability to collect blood samples from the pregnant woman and the biological father of the fetus (peripheral blood)
- Pregnant woman and father of the fetus aged ≥18 years
- Pregnant woman and father of the fetus able to comprehend the situation
- Person who has provided written consent
Exclusion Criteria:
- - Refusal of the pregnant woman or biological father to participate in the study
- Pregnancy before 11 weeks of amenorrhea or after 34 weeks of amenorrhea (to limit the risk of reporting results after birth)
- Pregnant women and/or biological fathers who are not affiliated to the national health insurance systel
- Pregnant women and/or biological fathers under some type of legal protection (guardianship, trusteeship, etc.)
- Pregnant women and/or biological fathers who are unable to express their consent
Organizational study:
In addition to the inclusion & exclusion criteria of the main study:
- Pregnant woman and/or biological father of fetus who provided oral consent to be interviewed
- Professionals (obstetrician, midwife, geneticist, biologist) willing to be interviewed or participate in a focus group
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients
Pregnant women with sonographic signs
|
family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
Collected during fetal and blood sampling performed as part of care for ACPA:
within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
|
Other: Health professionals
biologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
|
Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
number of etiological diagnosis common to the 2 analysis techniques : NIPD exomes and trio fetal ES
Time Frame: At baseline
|
At baseline
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NAMBOT PHRCI 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antenatal Congenital Malformations
-
Azienda Ospedaliera Universitaria Integrata VeronaInternational Centre of Birth DefectsUnknown
-
King's College Hospital NHS TrustKing's College LondonCompletedCongenital Disorders | Pulmonary Arteriovenous MalformationUnited Kingdom
-
JhpiegoBill and Melinda Gates Foundation; Addis Continental Institute of Public HealthTerminated
-
Hacettepe UniversityCompletedInner Ear Malformations
-
Pierre WauthyCompletedCongenital Heart MalformationsBelgium
-
Peking University Third HospitalPeking University; Peking University China Center for Health Development StudiesEnrolling by invitation
-
Centre Hospitalier Universitaire DijonRecruiting
-
Security Forces HospitalCompletedCongenital MalformationsSaudi Arabia
-
University of MichiganEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
Clinical Trials on Collection of clinical data
-
Centre Hospitalier Universitaire DijonCompletedCoronary Artery Bypass Graft | Anomalies in Glucose MetabolismFrance
-
University Hospital, Basel, SwitzerlandCompletedPatellar InstabilitySwitzerland
-
Heinrich-Heine University, DuesseldorfRecruitingAortic Stenosis | Aortic Aneurysm | Aortic Disease | Large Artery StiffnessGermany
-
Heinrich-Heine University, DuesseldorfRecruitingST-segment Elevation Myocardial Infarction (STEMI)Germany
-
Shanghai Zhongshan HospitalNot yet recruitingPreoperative Nutritional Status and Risk Factors Associated With Elderly Patients Undergoing Gastrectomy
-
Fadoi Foundation, ItalyUniversity of GenovaUnknown
-
Corporacion Parc TauliRecruitingMechanical Ventilation Complication | Weaning FailureSpain
-
Institut Paoli-CalmettesRecruiting
-
National Institute of Allergy and Infectious Diseases...Boston Children's Hospital; Benaroya Research InstituteCompletedSARS-CoV-2 | Coronavirus Disease 2019 (COVID-19)United States
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingCerebrospinal; DisorderFrance